It seems like there was a time when the Covid vaccine was all the rage — you saw it on every street corner, you heard it in every record shop, it was on the beach boardwalk and at the roller rink, just everywhere.
Alas, for the corporations that make it, its time seems to have come and gone:
Shares of BioNTech on Monday slid by more than 6% in morning trading after the German drugmaker shared a gloomy 2023 sales outlook for its Covid vaccine jointly developed with Pfizer.
Wow, really, a "gloomy outlook?" You're telling me people are growing tired of this weird, taxpayer-funded experimental injection that you apparently have to take like four times a year in order to sorta kinda hope that you might get a milder version of the illness you can still catch even though you took a "vaccine" to prevent it?
I would've thought that was the sort of thing that people would want to do every year, all the time, forever.
Really, though, it's pretty impressive the size of the cliff this thing is falling off of:
The drugmaker [is] forecasting Covid vaccine revenue to hit 5 billion euros, or $5.4 billion. That's a steep decline from the 17.3 billion euros, or more than $18 billion, in 2022.
That is just a mammoth decline — a full 70%. I don't know if that translates into 70% less demand or what, but it definitely means that more and more people are getting off the vax train and deciding that they don't need to get stuck with a "booster" every nine minutes.
